US-Listed In Vitro & In Vivo Diagnostic Substances — Total Assets Percentiles, FY 2025

Population: 18 US-listed companies (SIC 2835), fiscal year 2025; fiscal year ends 2025-12-28 to 2026-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$6.9M
25th percentile	$26.9M
Median	$42.2M
75th percentile	$808.2M
90th percentile	$3.3B
Mean	$954.0M
Minimum	$5.5M
Maximum	$5.8B

Methodology & sources
Total Assets as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2025 = fiscal years ending 2025-06-01 to 2026-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Total Assets percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/total-assets/2025